I.R.A. Istituto Ricerche Applicate S.p.A.
11
0
0
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Evaluating the Performance and Safety of the Medical Device Auralya® in the Treatment of Facial Dermal Tissue Defects
Role: lead
Evaluating the Performance and Safety of the Medical Device Plenhyage® in the Treatment of Dermal Tissue Defects
Role: lead
Evaluating Performance and Safety of the Medical Device Jalucomplex in the Treatment of Facial and Neck Tissue Defects
Role: lead
Evaluating the Performance and Safety of the Medical Device Janesse in the Treatment of Facial Dermal Tissue Defects
Role: lead
To Assess The Performance And Tolerance Of Janesse 20 In The Volume Restoration Of Labia Majora
Role: lead
To Evaluate the Performance and Safety of the Medical Device IRADYN in Subjects With Osteoarthritis of the Knee
Role: lead
Study to Evaluate the Performance and Safety of the Medical Device Plenhyage®
Role: lead
Study To Assess The Efficacy And Safety Of The Medical Device Iracross Versus Iraline Administered Intra-Articular To Patients With Knee Osteoarthritis
Role: lead
Evaluate The Performance And Safety Of The Medical Device Jalucomplex®
Role: lead
MD Auralia (HA Filler) in Treatment of Nasolabial Wrinkles
Role: lead
Open, Non-Comparative Study To Evaluate The Performance Of The Medical Device JANESSE®
Role: lead
All 11 trials loaded